Immunohistochemistry staining revealed significantly higher protein levels of RUNX2 in recurrent tumors and lung/liver metastasis than the ones in non-recurrent tumors (Fig. 8d), implying that RUNX2 overexpression correlated tightly with CRC progression. The gene discussed is RUNX2; the disease is colorectal carcinoma.